Cartalax Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What Cartalax Does & How It Works

What It Does - Functional Outcomes

In preclinical research, Cartalax has been documented to produce the following effects in cell culture and animal models:

• Shifts aging cells from a senescent, growth-arrested state toward a more proliferative, metabolically active pattern
• Supports cartilage cell (chondrocyte) division and stimulates production of the structural proteins that make cartilage resilient - type II collagen and proteoglycans
• Suppresses the enzymes that degrade connective tissue matrix (matrix metalloproteinases) while upregulating the proteins that keep those enzymes in check
• Reduces expression of tumor suppressor and cell cycle brake proteins associated with cellular aging (p53, p16, p21)
• Upregulates SIRT-6, a protein linked to DNA repair and cellular longevity
• Modulates gene expression in aging stem cells in directions associated with maintained regenerative capacity
• Reduces programmed cell death (apoptosis) in both young and aged cell populations

All of these outcomes are established in cell culture and animal models. None have been measured in human clinical trials.

How It Works - Mechanism of Action

Here is what makes Cartalax structurally different from the majority of research peptides. Most peptides work by binding to receptors on the outside of cells - like a key fitting a lock on the cell surface - which triggers a downstream signaling cascade. Cartalax bypasses that entire layer. It is small enough (333 Daltons) to pass through cell membranes and nuclear membranes directly, where it interacts with DNA itself.

DNA Minor Groove Binding: Direct Transcriptional Regulation (Evidence: In vitro - molecular modeling)

Cartalax forms non-covalent complexes with specific DNA sequences, particularly the alternating AT repeat motif d(ATATATATAT)2, through interactions in the DNA minor groove (the shallower of the two grooves that run along the outside of the DNA double helix). The two acidic residues in Cartalax (glutamic acid and aspartic acid) carry negative charges at physiological pH that create electrostatic complementarity with the groove. This binding was characterized through molecular modeling studies by Khavinson and colleagues, establishing the structural basis for the gene expression changes observed in cell culture experiments.

Cellular Senescence Marker Modulation (Evidence: In vitro - cell cultures)

Once inside the nucleus, Cartalax alters which genes are accessible to the cell's transcription machinery. The net effect in aging cell studies is a reduction in proteins that put the brakes on cell division. These include p53 (a tumor suppressor and senescence regulator), p16 (CDKN2A, which means cyclin-dependent kinase inhibitor 2A - a protein that blocks cell cycle progression), and p21 (CDKN1A, another cyclin-dependent kinase inhibitor that acts as a senescence marker). Simultaneously, proliferation marker Ki-67 increases by 20-30% and SIRT-6 - a protein associated with DNA repair and longevity - is upregulated. The combination represents a measurable shift in the gene expression pattern of aging cells toward a more youthful state.

Extracellular Matrix Homeostasis: MMP Regulation (Evidence: In vitro and animal models)

Connective tissue is maintained by a balance between enzymes that break it down (matrix metalloproteinases, or MMPs) and proteins that inhibit those enzymes (tissue inhibitors of metalloproteinases, or TIMPs). In aging tissue, this balance tips toward breakdown. In cell culture and animal model studies, Cartalax reduced expression of MMP-9 while upregulating TIMPs, shifting the balance back toward maintenance and synthesis. Enhanced production of type II collagen and proteoglycans was documented in chondrocyte studies.

Anti-Apoptotic Effects via Caspase-3 Reduction (Evidence: In vitro - multiple cell types)

Caspase-3 is the primary executioner enzyme in apoptosis (programmed cell death). In cell culture studies, Cartalax reduced caspase-3 activity in both young and aged cell populations. Combined with the proliferation marker increases, this means treated cells are simultaneously more likely to divide and less likely to execute the self-destruction program. In aging tissue where functional cell populations decline, this shift has theoretical benefits. The same effects, in the wrong biological context, have theoretical implications for cancer biology that remain uncharacterized.

Stem Cell Gene Expression Modulation (Evidence: In vitro - bone marrow mesenchymal stem cells)

In bone marrow mesenchymal stem cell studies, Cartalax produced 1.6- to 5.6-fold expression changes in a panel of genes relevant to stem cell aging. These include TERT (telomerase reverse transcriptase, the enzyme that maintains chromosome end caps) and FOXO1 (a transcription factor linked to stress resistance and longevity signaling). Whether these gene expression shifts translate to better tissue repair in a living organism is the open question the research has not yet answered.

Cartalax Molecular Profile

Structure reference: View on PubChem (CID 87815447) - Publishing team: retrieve 2D structure image from this link.

Structural context: The AED sequence corresponds to a motif found in the alpha-1 chain of type XI collagen, the structural protein critical for cartilage organization and extracellular matrix integrity. This structural homology is hypothesized to contribute to Cartalax's documented affinity for connective tissue cell types and its cartilage-specific research applications. Notably, the AED sequence is also the first three amino acids of Epithalon (AEDG), making Cartalax and Epithalon structurally related peptides despite having distinct research applications.

Cartalax Uses & Benefits

Cartilage Biology and Joint Tissue Research

Cartilage is one of the most difficult tissues to repair naturally. It has no blood supply of its own, which limits the delivery of repair materials, and its primary cell type - the chondrocyte - divides slowly. Researchers have used Cartalax to investigate whether the compound's documented effects on cell proliferation and matrix protein production can be applied to cartilage. Published cell culture studies found enhanced chondrocyte proliferation (confirmed by PCNA, or proliferating cell nuclear antigen, a standard marker of active cell division), upregulated type II collagen and proteoglycan synthesis, and improved structural measures of cartilage resilience. A rabbit cartilage defect model using peptide complexes that included Cartalax demonstrated filling with hyaline-like cartilage - the native, functional tissue type - rather than the inferior fibrocartilage that typically fills untreated defects. (Evidence: Preliminary - Linkova et al., 2023; Myakisheva et al., 2023)

Cellular Aging and Senescence Research

The most extensively published application of Cartalax is in cellular aging models. Studies in fibroblast cultures and kidney cell cultures from both young and aged animal sources documented consistent reductions in p53, p16, and p21 alongside increased Ki-67 and SIRT-6. This pattern is interpreted as a shift toward a more youthful gene expression state. The fact that effects were consistent regardless of whether cells came from young or aged sources suggests the mechanism operates across different stages of cellular aging rather than being limited to a specific phase. Research from the Khavinson program positions this as a potential approach to slowing cellular senescence at the gene expression level. The translation from cell culture findings to outcomes in living organisms has not been directly measured. (Evidence: Preliminary - Lin'kova et al., 2016; Chalisova et al., 2015)

Skin Biology and Dermal Fibroblast Research

Dermal fibroblasts - the cells responsible for producing collagen and maintaining skin structure - were among the first cell types studied in the Khavinson bioregulator research program. Cartalax effects on fibroblast cultures include the proliferation marker improvements documented in the Lin'kova studies, as well as improvements in microcirculation markers and functional activity measures. A 2020 review by Khavinson and colleagues specifically addressed the application of short bioregulatory peptides, including Cartalax, to skin aging research. No skin-specific clinical trial data has been published. (Evidence: Preliminary - Khavinson et al., 2020)

Kidney Cell Regeneration Research

Some research programs describe Cartalax as having been isolated from kidney tissue extracts (others describe cartilage - this discrepancy is noted in the literature), and kidney cell cultures have been directly studied as a model for its activity. Chalisova et al. (2015) documented increased cell proliferation in kidney tissue cultures from both young and old animals, with decreased senescence markers and upregulated SIRT-6. This adds kidney tissue to the list of cell types where the senescence-modulating effects have been observed. Whether this has any practical relevance to renal health outcomes in living organisms has not been investigated. (Evidence: Preliminary - Chalisova et al., 2015)

Stem Cell Aging and Regenerative Biology Research

The mesenchymal stem cell study by Ashapkin et al. (2020) occupies a distinct research domain: rather than studying mature differentiated cells, it examined how Cartalax affects the gene expression of stem cells responsible for producing multiple tissue types. The 1.6- to 5.6-fold gene expression changes documented for TERT, FOXO1, IGF1, TNKS2, and NF-kappa-B in aging stem cells represent some of the most mechanistically significant findings in the Cartalax literature. Stem cell aging is a fundamental driver of tissue repair capacity decline. The TERT upregulation in particular - given telomerase's role in maintaining telomere length and cellular replicative potential - has made this study a reference point in longevity research discussions. Functional consequences for tissue regeneration in living organisms have not been measured. (Evidence: Preliminary - Ashapkin et al., 2020)

Where This Guide Comes From

Cartalax Results & Timelines

Cartalax occupies unusual territory when it comes to reported timelines. No human clinical trial data exists to anchor expectations, and the published preclinical studies measured outcomes at study endpoints rather than tracking week-by-week progression. What follows reflects the available preclinical data and the experience reported by users exploring the Khavinson bioregulator class, attributed to the MyPeptidePal Knowledge Base where it draws on aggregated protocol data rather than individual anecdotes.

Cartilage and Connective Tissue Applications

• Week 1-2: Minimal subjectively detectable change is typical at this stage; the mechanism works at the gene expression level, which produces gradual shifts rather than acute responses
• Week 3-6: Users exploring joint-focused applications in the Khavinson bioregulator community report this as the window where any meaningful subjective change becomes noticeable, if it occurs
• Week 6-12: The most commonly discussed window for any structural or functional connective tissue changes; animal model studies measuring cartilage matrix outcomes used protocols in this general timeframe
• Beyond 12 weeks: Published animal cartilage research does not characterize longer-term outcomes systematically; the in vivo rabbit model measured defect repair at a fixed endpoint rather than tracking progressive improvement

Cellular Aging and Longevity Applications

• Week 1-4: Gene expression changes at the cellular level are not subjectively detectable; this stage is below the threshold of any user-reported awareness
• Week 4-12: Some users in longevity-focused Khavinson peptide communities report this as a window where subjective well-being measures may shift, though distinguishing compound-specific effects from other protocol variables is not possible in uncontrolled use
• Beyond 12 weeks: No published outcome data characterizes longer timelines for Cartalax specifically; Khavinson bioregulator programs more broadly have studied repeat cycle approaches over months to years in animal longevity models

Skin Biology Applications

• Week 2-4: In fibroblast culture models, proliferation marker changes were measurable within the study window; in real-world application, no clinical skin trial timeline data has been published
• Week 6-12: Users combining Cartalax with other Khavinson bioregulators in skin-focused protocols report this as the general observation window, with the caveat that multi-compound protocols make attribution difficult

How to Administer Cartalax

Subcutaneous Injection (SubQ)

Subcutaneous injection into the fatty tissue layer just below the skin is the only administration route with formal documentation in published Cartalax research. Animal studies used subcutaneous dosing as the primary delivery method, providing systemic distribution and bypassing the gastric degradation that limits oral bioavailability. Common injection sites for subcutaneous peptide administration include the abdomen, outer thigh, and upper arm.

Intramuscular Injection (IM)

Intraperitoneal injection was used in some rodent studies for controlled, rapid dosing - a research-context route that does not directly translate to human practice. Intramuscular injection has been explored by users of Khavinson-class bioregulators, though no published pharmacokinetic comparison of IM versus SubQ exists for Cartalax specifically. For most short bioregulatory peptides in this class, SubQ is the primary documented route.

Oral

Oral administration has been investigated in Russian clinical practice contexts for Khavinson-class bioregulators, but bioavailability is limited by proteolytic degradation in the gastrointestinal tract. Stomach acid and digestive enzymes break peptide bonds before significant amounts of intact Cartalax can reach systemic circulation. The extent of this degradation has not been formally quantified for Cartalax specifically, and no published bioavailability comparison between oral and injectable routes exists. Some users of this peptide class have used enteric-coated oral formulations, though the pharmacokinetic benefit of this approach for a tripeptide has not been established.

Sublingual

Sublingual delivery - placing solution under the tongue for absorption through the oral mucosa - has been explored as a partial alternative to injection for Khavinson bioregulators. Sublingual absorption bypasses the gastric degradation problem because the oral mucosal membrane allows direct absorption into circulation without passing through the stomach. Pharmacokinetic data for sublingual Cartalax has not been published, so the bioavailability advantage relative to oral or injectable routes is theoretical rather than measured.

Cartalax Dosage & Cycle Length

Overall dosing range: 10 mcg/kg per day in published animal studies - no human dosing data exists

The only peer-reviewed dosing data available for Cartalax comes from rat and rabbit research models, where 10 mcg/kg per day was the most consistently used protocol across aging, cartilage, and kidney studies. There is no published human clinical trial data, no practitioner-established human dosing consensus, and no formal pharmacokinetic characterization that would support extrapolating animal doses to humans. What follows reflects what the published research used and what the broader community of Khavinson bioregulator users has explored - not established human protocols.

How the goal shifts where you land:

• Low end of range: In the context of bioregulator research, lower doses are more commonly associated with maintenance and cellular homeostasis applications - preserving what exists rather than aggressively driving change
• Mid range: The published animal study dose of 10 mcg/kg sits in what practitioners familiar with this peptide class describe as a moderate, tissue-targeted range
• High end of range: Higher experimental doses have not been prominently featured in published Cartalax research; the compound's DNA-binding mechanism operates at very small concentrations given its direct nuclear access (evidence grade: Preliminary - animal models only)

Frequency: Daily administration was the standard protocol in published animal aging studies

Cycle length: Animal study protocols varied; typical aging research models ran weeks to months. Among users of Khavinson-class bioregulators more broadly, cycle patterns of 10 to 30 days are common, often repeated two to three times per year, though no published data establishes this as optimal or validated for Cartalax specifically.

Loading protocols: No loading or front-loading protocol has been documented in published Cartalax research.

A note on translation: animal-to-human dose scaling is not straightforward. Body surface area, metabolic rate, tissue distribution, and proteolytic clearance all differ between species in ways that make direct mcg/kg conversion unreliable. This is a recognized limitation of the available data - not a gap that can be bridged by arithmetic.

Cartalax Vial Sizes, Costs & Quality

Common vial sizes: 2 mg and 5 mg are the most commonly available sizes for research-grade Cartalax; 10 mg vials are available from some suppliers

Typical cost range: $40-$90 per vial for U.S.-manufactured research-grade Cartalax at current market pricing - varies by supplier, vial size, and purity level. Cartalax is a relatively low-volume research peptide compared to more widely studied compounds like BPC-157 or TB-500, which contributes to higher per-milligram pricing at some suppliers.

Storage - lyophilized (dry powder):

• Temperature: -20 degrees C for long-term storage; 2-8 degrees C for short-term
• Shelf life: Stable for 12-24 months when stored properly at -20 degrees C
• Light sensitivity: Store in opaque or amber containers; avoid prolonged light exposure

Storage - reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C immediately after reconstitution
• Use window: Typically 14-28 days once reconstituted, though specific stability data for Cartalax in solution has not been formally published

Normal appearance after reconstitution: Cartalax dissolves into a clear, colorless solution. Given its small molecular size (333 Da) and confirmed water solubility, it should go fully into solution without particulates or cloudiness. Any persistent cloudiness or visible particulate matter after thorough mixing would be atypical.

Signs of degradation: Heavy or persistent cloudiness in a solution that should be clear, visible particulates or chunks that do not dissolve, discoloration (yellowing or browning), or any unusual odor. Degraded peptide should not be used.

Quality Considerations

Cartalax is a low-volume research peptide, and that creates a specific quality risk. When demand is limited, the financial incentive for rigorous synthesis and testing is lower - which means the gap between responsible suppliers and cut-rate operations is wider than it is for high-volume peptides. The key quality variable for a tripeptide like Cartalax is synthesis purity: shorter peptides are technically simpler to produce, but impure synthesis still yields active-looking vials with significant amounts of truncated sequences, incorrect isomers, or residual synthesis reagents that cannot be detected without HPLC analysis. The only real protection is a supplier who provides third-party certificates of analysis with each batch, manufactures domestically under documented quality standards, and tests for endotoxins. Paying significantly below market rate for a low-volume research peptide is rarely a bargain.

Cartalax Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active malignancy or history of cancer: Cartalax reduces expression of p53, p16, and p21 (proteins that function as tumor suppressors and cell cycle regulators) and reduces caspase-3 activity, which is part of programmed cell death. In a cancer context, suppressing these mechanisms is theoretically counterproductive and potentially hazardous. No oncological safety data has been published. This represents a theoretical contraindication based on mechanism, not an observed adverse event.
• Concurrent use with chemotherapy or oncological treatment: No drug interaction data exists; mechanism raises theoretical concerns
• Individuals with undiagnosed or suspected proliferative conditions: The compound's effects on senescence and apoptosis markers have not been studied in these contexts
• Insufficient data to confirm safety in individuals with autoimmune conditions: NF-kappa-B pathway modulation has been documented; functional immune consequences are uncharacterized

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Individuals with personal or family history of cancer: Given the theoretical concerns around p53 and apoptosis pathway modulation, caution is warranted until oncological safety data exists
• Individuals taking medications that affect cell cycle regulation or immune function: No interaction data available; theoretical overlap exists with the compound's documented mechanisms

Red Flags - Stop Use and Seek Medical Attention If:

• Unexpected masses, lumps, or rapidly changing skin lesions during or following a protocol
• Severe or worsening systemic inflammation signs (given incomplete characterization of NF-kappa-B pathway effects)
• Any unusual immune or inflammatory response following administration
• Injection site reactions that progress beyond mild local redness or that do not resolve within 48-72 hours

Drug and Compound Interactions

No drug interaction studies have been published for Cartalax in any accessible peer-reviewed literature. The compound has no characterized interaction profile with medications, other peptides, or compounds. Given its mechanism of action at the gene expression level (specifically its effects on tumor suppressor proteins, apoptosis pathways, and NF-kappa-B signaling), theoretical overlap exists with anticoagulants, immunomodulatory drugs, corticosteroids, and oncological medications. None of these interactions have been studied. Anyone taking prescription medications should approach this compound with particular caution given the complete absence of interaction data.

Cartalax Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability

Published pharmacokinetic data for Cartalax is limited. In rodent studies, cellular uptake following subcutaneous administration was described as occurring within minutes, consistent with the compound's small molecular size of 333 Daltons. This small size allows passive diffusion across cell membranes and nuclear membranes without requiring receptor-mediated transport. That passive entry is the mechanistic prerequisite for its documented DNA-binding activity. Bioavailability via the subcutaneous route is presumed to be high based on peptide class behavior. Formal Cmax (peak plasma concentration), Tmax (time to peak concentration), and AUC (area under the curve, a measure of total drug exposure) measurements have not been published.

Distribution

Nuclear localization has been confirmed in cell studies, which is a prerequisite for the proposed mechanism of action. Distribution in animal models has been observed in skin, kidney, cartilage, and connective tissue. This aligns with the compound's documented research applications and structural homology to type XI collagen. Whether Cartalax crosses the blood-brain barrier has not been characterized.

Half-Life

Plasma half-life has not been formally measured or published for Cartalax. Based on its tripeptide structure and the behavior of similar short bioregulatory peptides, rapid plasma clearance through standard peptidase activity is expected. The important nuance is this: the duration of biological effect (hours to days) extends well beyond the presumed plasma half-life. The primary action occurs at the level of gene expression, so changes triggered at the DNA level persist after the peptide itself has been metabolized.

Metabolism & Elimination

Cartalax is degraded by standard peptidase and protease pathways, yielding its three constituent amino acids: alanine, glutamic acid, and aspartic acid. These are then recycled through normal amino acid metabolism. Renal elimination of metabolites is presumed but has not been formally characterized. No evidence of tissue accumulation was noted in chronic dosing animal studies at published doses.

Mechanistic Research

DNA Minor Groove Binding: Molecular Modeling Characterization (Evidence: In vitro - molecular modeling)

Molecular modeling studies characterized the energetically favorable interaction between the AED tripeptide sequence and the d(ATATATATAT)2 motif in the DNA minor groove. The two acidic residues in Cartalax (glutamic acid and aspartic acid) carry negative charges at physiological pH that contribute to the electrostatic complementarity with the minor groove. This characterization established the structural basis for the transcriptional regulatory effects observed in cell culture studies.

Cellular Senescence Marker Modulation (Evidence: In vitro - fibroblast and kidney cell cultures - Lin'kova et al., 2016; Chalisova et al., 2015)

Studies in aging fibroblast and kidney cell cultures documented reductions in p53 (up to 25%), p16 (CDKN2A), and p21 (CDKN1A) - three proteins that function as brakes on cell division and markers of cellular senescence. Concurrent increases in Ki-67 (20-30% in aging cultures), SIRT-6, and CD98hc (SLC3A2, a membrane transporter associated with cellular regeneration and nutrient uptake) indicated a shift toward a more proliferative and metabolically active cell state. Effects were consistent across different passage numbers, suggesting the mechanism operates regardless of whether cells are early-passage (relatively young) or late-passage (aged and senescent).

MMP Regulation and ECM Homeostasis (Evidence: In vitro and animal models)

In aging fibroblast and cartilage cell cultures, Cartalax reduced expression of MMP-9 while upregulating tissue inhibitors of metalloproteinases (TIMPs). Matrix metalloproteinases are the primary enzymes responsible for breaking down collagen and proteoglycans in connective tissue; their overexpression in aging tissue is a key driver of cartilage degradation and loss of structural integrity. The shift toward TIMP upregulation alongside MMP suppression represents a measurable change in the balance between catabolic and anabolic forces in connective tissue homeostasis.

Anti-Apoptotic Effects via Caspase-3 Reduction (Evidence: In vitro - multiple cell types)

Reduced caspase-3 activity was documented in both young and aged cell cultures treated with Cartalax, alongside the increases in Ki-67 and decreases in senescence markers. Caspase-3 is the terminal executioner in most apoptotic pathways; its reduction means fewer cells executing the self-destruction program. In the context of aging tissue where functional cell populations decline, reduced apoptosis combined with increased proliferation represents a net positive shift in cell population dynamics - at least in culture. The oncological implications of this effect in a living organism with existing cellular damage remain uncharacterized.

Stem Cell Gene Expression Modulation (Evidence: In vitro - bone marrow mesenchymal stem cells - Ashapkin et al., 2020)

In bone marrow mesenchymal stem cell studies, Cartalax produced 1.6- to 5.6-fold expression changes for IGF1, FOXO1, TERT, TNKS2, and NF-kappa-B. The TERT upregulation is significant because telomerase (the enzyme TERT encodes) extends telomeres, the protective end caps on chromosomes that shorten with each cell division. FOXO1 upregulation connects to stress resistance and longevity signaling. The magnitude of the TERT effect has attracted particular attention in longevity research discussions. Functional consequences in stem cell behavior and tissue regeneration outcomes have not been measured with outcome-level data.

Condition-Focused Research

Cartilage Biology and Joint Tissue Repair {#research-cartilage}

A 2023 study by Myakisheva and colleagues examined Cartalax effects on chondrocyte cultures. They measured proliferation via PCNA (proliferating cell nuclear antigen, a standard marker of active cell division) expression. Both stimulation of chondrocyte division and improvements in cartilage matrix resilience and elasticity were documented. In parallel, a 2023 study by Linkova and colleagues used young and aged rat chondrocyte cultures to demonstrate enhanced production of type II collagen and proteoglycans - the two primary structural components of functional cartilage. Type II collagen provides tensile strength; proteoglycans provide the hydration and compression resistance that makes cartilage effective as a load-bearing tissue. An in vivo rabbit cartilage defect model using peptide complexes that included Cartalax demonstrated filling with hyaline-like cartilage rather than fibrocartilage. This is a meaningful distinction because hyaline cartilage has functional mechanical properties while fibrocartilage is structurally inferior repair tissue. (Evidence: Preliminary - Myakisheva et al., 2023; Linkova et al., 2023)

Cellular Aging: Skin Fibroblast and Kidney Cell Models {#research-aging}

Lin'kova et al. (2016) documented Cartalax effects in aging fibroblast cultures using immunofluorescent confocal microscopy. They found 20-30% increases in Ki-67 and reductions in p53, p16, and p21 expression across multiple passage levels. CD98hc (a membrane transporter associated with cellular regeneration) was also upregulated. Chalisova et al. (2015) examined kidney cell cultures from both young and old animals, finding increased proliferation alongside decreased senescence markers and upregulation of SIRT-6. A 2019 study by Gutop and colleagues confirmed these effects across varying cell passage numbers, suggesting the mechanism is not limited to specific aging stages. (Evidence: Preliminary - Lin'kova et al., 2016; Chalisova et al., 2015)

Stem Cell Biology: Mesenchymal Stem Cell Gene Expression {#research-stemcell}

Ashapkin et al. (2020) examined Cartalax effects on bone marrow mesenchymal stem cells, finding 1.6- to 5.6-fold expression changes in a panel of genes with direct relevance to stem cell aging and regenerative capacity. TERT upregulation is significant because telomerase extends telomeres, the protective end caps on chromosomes that shorten with each cell division. FOXO1 upregulation connects to stress resistance and longevity signaling. IGF1 changes affect growth and tissue repair signaling. The magnitude of the TERT effect has attracted attention in longevity research circles. The functional consequences of these gene expression changes in stem cell behavior and tissue regeneration outcomes have not been measured. (Evidence: Preliminary - Ashapkin et al., 2020)

Skin Aging: Short Peptide Review Evidence {#research-skin}

The 2020 review by Khavinson and colleagues in Advances in Gerontology addressed short bioregulatory peptides including Cartalax in the context of skin aging regulation. Dermal fibroblast function, microcirculation markers, and structural protein production were the primary endpoints documented across the relevant studies covered in the review. The review situates Cartalax within the broader Khavinson bioregulator program. No clinical skin trials have been published. (Evidence: Preliminary - review of in vitro fibroblast studies - Khavinson et al., 2020)

Safety & Tolerability Research

Available safety data for Cartalax is confined to animal studies and cell culture observations. In the published rodent aging studies using doses of 10 mcg/kg per day, no specific adverse effects or organ toxicity signals were documented at the reported doses. Chronic dosing animal studies did not find evidence of tissue accumulation. No formal toxicology studies have been published in accessible English-language literature. The most significant theoretical safety considerations (reduced expression of tumor suppressor proteins p53, p16, p21 and decreased apoptotic activity) have not been examined in oncological research contexts. The NF-kappa-B upregulation finding adds a further layer of uncharacterized complexity. In the absence of Phase I human safety data, the full tolerability profile of Cartalax in humans is unknown.

Research Limitations

The evidence gaps for Cartalax are specific and matter for reading the research honestly. Here is what we know and what we do not.

All published research comes from a single Russian program led by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. No outside labs have independently replicated the findings. That is a real constraint on how much confidence to place in the results.

Every human-relevant study used cell cultures or animal models. No Phase I, II, or III human clinical trials have been published anywhere in accessible literature. Basic pharmacokinetic data (half-life, peak plasma levels, total drug exposure) has not been published. Long-term safety in any species has not been formally documented.

The most specific gap is oncological safety. Cartalax reduces tumor suppressor proteins and slows programmed cell death. What that means for someone with existing pre-malignant cells has not been studied. That question remains open.

Is Cartalax Legal? Regulatory & Sports Status

FDA status: Cartalax is not approved for any human therapeutic indication by the FDA. It is not classified as a dietary supplement under DSHEA. In the United States, it is available for purchase as a research compound only - not legal for human consumption or clinical administration.

Research Use Only (RUO): In the United States and most Western jurisdictions, Cartalax is classified as a research compound. This classification means it can legally be purchased and held for laboratory or scientific research purposes. It is not approved for human use and does not have IND (Investigational New Drug) status. It is not accessible through licensed compounding pharmacies for any indication.

WADA / USADA status: Specific WADA prohibited list status for Cartalax has not been confirmed in available sources. However, WADA's S0 category prohibits all non-approved pharmacological substances with no therapeutic justification - a category that encompasses research peptides like Cartalax by default. Athletes subject to anti-doping regulations should assume any research peptide is prohibited unless explicitly confirmed otherwise. Consult the current WADA Prohibited List and your sport's governing body directly.

Country-specific notes: In Russia, bioregulatory peptides developed by the Khavinson research program have in some cases been made available as dietary supplements. Whether this applies specifically to Cartalax has not been confirmed in available sources. The European Union, Australia, and Canada treat it as a research compound without registered therapeutic or supplement status. Regulatory frameworks and import rules differ significantly by jurisdiction - users are responsible for understanding the rules in their location.

Detection: No WADA-approved analytical test specifically for Cartalax has been identified in available sources. Given its short amino acid sequence and rapid metabolism to common amino acids (alanine, glutamic acid, aspartic acid), detection presents analytical challenges. This is an open question rather than a confirmed picture.

Cartalax vs. Alternatives

Commonly Paired With - Synergistic Stacks

• Cartalax + Epithalon (Epitalon): These two peptides share a partial sequence - Epithalon is the tetrapeptide AEDG, which contains the AED motif of Cartalax with an additional glycine. Both work through the Khavinson bioregulator framework and have overlapping effects on cellular senescence markers. They are frequently discussed together in longevity-focused protocols, with Epithalon contributing telomerase activation research and Cartalax contributing cartilage and connective tissue-specific activity.
• Cartalax + BPC-157: BPC-157 is the most widely researched peptide for connective tissue repair and has a more developed evidence base for joint and tissue recovery. Some users exploring joint health combine the two, with BPC-157 addressing the growth factor and angiogenesis side of repair while Cartalax is targeted at the matrix remodeling and chondrocyte proliferation side. These two compounds have different mechanisms and the combination is theoretical rather than studied.
• Cartalax + TB-500 (Thymosin beta-4): TB-500 is studied for its effects on actin dynamics, cell migration, and tissue repair. Combinations with Cartalax have been discussed in connective tissue recovery contexts, though no published combination data exists. Stacking information is for educational context - individualized stack protocols live inside MPP.

Alternatives - When Another Peptide May Be Considered

Epithalon (Epitalon) Epithalon is the most closely related peptide to Cartalax, sharing the AED sequence as its first three amino acids. It has a more extensive published evidence base, including telomerase activation research and animal longevity studies. Someone primarily interested in systemic anti-aging effects at the gene expression level and telomere biology would find Epithalon more extensively documented. Cartalax is the more targeted option when cartilage and connective tissue specificity is the priority.

BPC-157 BPC-157 has a substantially larger published evidence base for connective tissue repair, angiogenesis, and joint recovery than Cartalax, including a broader range of animal model types and some limited human data. Someone with a primary goal of injury recovery or joint tissue support who wants the compound with the most preclinical evidence behind it would typically start with BPC-157 rather than Cartalax.

TB-500 (Thymosin beta-4) TB-500 is studied for tissue repair and cell migration through the actin-binding pathway and has been explored in cartilage contexts. Its evidence base in connective tissue is more developed than Cartalax's, with broader animal model coverage. Like Cartalax, human clinical trial data is limited.

Comparison table:

Build Your Cartalax Peptide Protocol

FAQs

What is Cartalax?

Cartalax is a synthetic tripeptide bioregulator (sequence: Ala-Glu-Asp) developed by Professor Vladimir Khavinson's program in Russia. Unlike most research peptides, it enters the cell nucleus and interacts directly with DNA to modulate gene expression, rather than binding to surface receptors.

What does Cartalax do?

In preclinical research, Cartalax reduces cellular senescence markers (p53, p16, p21), increases the proliferation marker Ki-67 in aging cell cultures, supports cartilage cell division and structural protein production, and modulates gene expression in aging stem cells. All effects are from cell culture and animal studies - no human clinical trials have been published.

How long does Cartalax take to work?

No human timeline data exists. In animal and cell culture research, effects on gene expression and proliferation markers were measured at study endpoints rather than tracked week by week. The compound's gene expression mechanism produces effects that outlast the peptide itself, but any timeline in circulation is extrapolated from preclinical models or user reports.

What is the typical dose of Cartalax?

The only peer-reviewed dosing data comes from rat and rabbit studies, where 10 mcg/kg per day was the most consistent protocol. No human clinical dosing has been established. Animal doses cannot be directly converted to human doses, and MyPeptidePal can help contextualize available data within a personalized framework.

Is Cartalax legal?

In the United States, Cartalax is an unscheduled research compound - legal to purchase for laboratory research but not approved for human use by the FDA. Its status varies by country, with no registered pharmaceutical or supplement status in the EU, Australia, or other major jurisdictions. Athletes subject to WADA rules should treat it as potentially prohibited under the S0 category.

Can Cartalax be taken orally?

Oral bioavailability is limited by proteolytic degradation in the gastrointestinal tract - stomach acid and digestive enzymes break down the peptide before significant amounts reach systemic circulation. Sublingual delivery has been explored as a partial alternative, but pharmacokinetic data for that route is also unpublished. Subcutaneous injection, used in published research, is the only delivery method with formal documentation.

How is Cartalax different from Epithalon?

Cartalax (AED) and Epithalon (AEDG) share the first three amino acids of their sequence - Epithalon adds a glycine at the end. Epithalon has a more extensively published evidence base for telomerase activation and systemic anti-aging effects. Cartalax research focuses more specifically on cartilage biology, connective tissue matrix regulation, and chondrocyte function.

Does Cartalax need to be refrigerated?

In lyophilized (dry powder) form, Cartalax should be stored at -20 degrees C for long-term preservation or at 2-8 degrees C for shorter-term storage. Once reconstituted, it requires refrigeration at 2-8 degrees C and should be used within 14-28 days. Protect from light and temperature fluctuations throughout storage.

What are the main safety concerns with Cartalax?

The most significant theoretical concern is its effects on tumor suppressor proteins (p53, p16, p21) and apoptosis pathways (caspase-3 reduction). In individuals with existing pre-malignant conditions or cancer, modulating these pathways could be counterproductive or harmful. No human safety data has been published, and the interaction profile with any medications is completely unknown.

Final Thoughts

Cartalax holds an unusual place in the research peptide landscape. It is one of the few short bioregulatory peptides with a mechanistically characterized mode of action - DNA minor groove binding and transcriptional regulation - that genuinely distinguishes it from receptor-targeting compounds. The research documenting its effects on cellular senescence markers, chondrocyte biology, extracellular matrix regulation, and stem cell gene expression is internally consistent. It builds a coherent preclinical picture. The sequence correspondence to a collagen alpha-chain motif, the documented affinity for connective tissue cell types, and the cartilage-specific research findings give the compound a logical structural identity that many research peptides lack.

The counterweight to that picture is straightforward. Virtually all published research on Cartalax comes from a single Russian research program. No outside labs have confirmed the findings. No human trials have been run. The pharmacokinetic profile is incomplete. The safety implications of reducing p53, p16, p21, and caspase-3 activity have not been studied in any cancer-relevant model. These are not minor details. They are basic questions about whether the compound is safe and effective in humans - questions that have no answers yet. Anyone engaging with Cartalax as a research compound should go in knowing exactly where the map runs out.

Regulatory status reflects this evidence gap directly. Cartalax is a research compound in the United States and most Western jurisdictions - not approved for human use, not accessible through compounding pharmacies, and not evaluated in any clinical pathway. If you want to understand how available protocol data applies to your specific health context and goals, MyPeptidePal can help frame that picture and build a structured protocol - while being clear about exactly what the evidence does and does not support for this compound.

References

1. Khavinson, V. K., et al. (2020). Short peptides: regulation of skin function during aging. Advances in Gerontology, 33(1), 46-54.

2. Linkova, N. S., et al. (2023). Molecular aspects of the peptide regulation of chondrogenesis during aging. International Journal of Molecular Sciences, 24(5), 4608.

3. Myakisheva, S. N., et al. (2023). Effect of peptides on proliferative activity of chondrocytes and characteristics of the cartilage extracellular matrix. Bulletin of Experimental Biology and Medicine, 174(4), 489-492.

4. Ashapkin, V. V., et al. (2020). Peptide regulation of aging: from chemistry to clinic. Biochemistry (Moscow), 85(12), 1549-1562.

5. Lin'kova, N. S., et al. (2016). Peptide regulation of skin fibroblast functions during their aging in vitro. Bulletin of Experimental Biology and Medicine, 161(1), 175-178.

6. Chalisova, N. I., et al. (2015). Short peptides stimulate cell regeneration in kidney tissue culture during aging. Advances in Gerontology, 28(2), 255-260.